Loading…
Loading…
On October 23, 2026, Trulieve Cannabis Corp (TRLV) shares fell 4.6%, currently priced at $10.42. This move comes amid a 52-week range of $4.62 to $13.28, indica
Trulieve Cannabis (NYSE: TRLV - Get Free Report) and Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 26.2% of Sol-Gel
Here, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
TALLAHASSEE, Fla., Oct. 7, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced the full repayment of an approximately $65 million mortgage notes payable secured by a cultivation site in Jefferson County, Florida, thereby reducing outstanding debt to approximately $225 million.
TALLAHASSEE, Fla., Oct. 6, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV ) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., will hold a conference call on Thursday, November 5, 2026 at 8:30 AM Eastern Time following the release of its third quarter 2026 financial results.
The two pot companies had higher second-quarter profit. Their balance sheets are stronger than other companies in the sector.
Trulieve Cannabis Corp. (NYSE: TRLV - Get Free Report) shares gapped down prior to trading on Wednesday. The stock had previously closed at $12.41, but opened at $10.86. Trulieve Cannabis shares last traded at $10.7260, with a volume of 1,386,029 shares changing hands. Wall Street Analyst Weigh In A number of brokerages have issued reports on
I reiterate my Buy rating on AdvisorShares Pure US Cannabis ETF despite the DEA pausing rescheduling hearings. MSOS remains attractive as the rescheduling catalyst is delayed, not canceled, and underlying holdings appear reasonably valued. Trulieve Cannabis Corp., MSOS's largest holding, stands out due to its Florida medical sales focus and normalized tax rates.